Le Lézard
Classified in: Health
Subjects: TRI, FDA

KeifeRx Receives FDA Acceptance of Investigational New Drug for Phase 3 Study of Nilotinib BE in Early Alzheimer's Disease

WASHINGTON, July 30, 2021 /PRNewswire/ -- KeifeRx, LLC, an emerging clinical-stage biotechnology company specializing in the discovery and development of new treatment options for neurodegenerative diseases, announced today that the company received an acceptance of its Investigational New Drug (IND) application from the United States Food and Drug Administration (FDA) to launch a Phase 3 trial named NILEAD for Nilotinib BE.

The safety and efficacy of a Nilotinib BE will be investigated in individuals with dementia due to Alzheimer's disease with abnormal levels of brain amyloid and supporting clinical diagnosis of early Alzheimer's disease. "We are very pleased that KeifeRx's first IND has been accepted by the FDA," said Charbel Moussa, MBBS, PhD, Associate Professor at Georgetown University and Co-Founder and Director of KeifeRx's Scientific Advisory Board. "Our Phase 3 study provides us the opportunity to gain valuable insights about the potential effectiveness of Nilotinib BE in treating early Alzheimer's."

"We are excited about this major milestone for KeifeRx, and the chance to demonstrate the capabilities of our tyrosine kinase inhibitors (TKI) platform in neurodegeneration," said Chris Hoyt, CEO of KeifeRx. "We are looking forward to the successful execution of this program and the ability to help people affected by such a debilitating disease."

Alzheimer's disease is a disorder that affects over 6 million people in the United States and more than 44 million people worldwide.

About NILEAD: 
KeifeRx will launch a national, multicenter, placebo-controlled, double-blind study of Nilotinib BE in early Alzheimer's disease. A total of 1275 patients will be randomized into three groups (1:1:1) in which they will receive placebo or one of two doses of Nilotinib BE for 72 weeks. The primary objectives of the study are to investigate the safety and efficacy of Nilotinib BE on the progression of dementia in early Alzheimer's disease. A biomarker sub-study will investigate the effects of Nilotinib BE on amyloid brain burden as well as other makers of Alzheimer's pathology.

About KeifeRx: 
KeifeRx is clinical-stage life sciences company that focuses on a family of drugs called tyrosine kinase inhibitors (TKIs) that trigger degradation of malfunctioning proteins, mitigating their pathological toxic effects. Georgetown University owns several issued patents and pending patent applications on the underlying technology that relates to the use of TKIs for treatment of neurodegenerative diseases with Charbel Moussa as an inventor. KeifeRx has an exclusive option to license to the intellectual property from Georgetown University. KeifeRx was founded in 2019 to redefine the treatment experience for patients suffering from neurodegenerative diseases and movement disorders which include but are not limited to, Alzheimer's Disease, Lewy Body Dementia and Parkinson's Disease. KeifeRx is a DMV Angels backed company.

For more information on KeifeRx, please visit https://www.keiferx.com, https://www.linkedin.com/company/keiferx, or contact: Pasha Jahangiri, 202-810-0580, 315553@email4pr.com

1356 Beverly Road, Suite 300
McLean, Virginia 22101


These press releases may also interest you

at 18:20
Worcester Polytechnic Institute (WPI) researcher Loris Fichera has developed a flexible, slimmed-down robotic laser probe for endoscopic larynx surgeries that could reduce recovery time for patients and cut health care spending by shifting procedures...

at 18:15
The "Global Industrial Radiography Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Technique (Film-based Radiography and Digital Radiography); End-User Industry" report has been added to ResearchAndMarkets.com's offering. The...

at 18:05
Summary Product: Ombrelle Garnier Complete Dry Mist Spray sunscreen, SPF 30 and SPF 60 (DIN 02415313 and DIN 02415402) Issue: Ombrelle Canada is recalling all lots due to elevated levels of benzene, which may pose serious health risks. What to...

at 18:00
Ensuring healthy lives and promoting physical and mental well-being is essential to sustainable development. Currently, the world is facing a global health crisis unlike any other. Global health has increasingly gained international visibility and...

at 18:00
Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") , a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers, premium cancer hospitals, and specialty cancer...

at 18:00
The Board of Directors of the Society to Improve Diagnosis (SIDM) announced today that after an extensive national search Jennie Ward-Robinson, PhD has been appointed as the organization's new Chief Executive Officer. Dr. Ward-Robinson will succeed...

News published on 30 july 2021 at 08:33 and distributed by: